SLC5A2 and type 1 diabetes mellitus: However, SGLT2i treatment increased the risk of diabetic ketoacidosis (OR 3.52, 95% CI [2.16-5.71]) and genital tract infections (OR 3.69, 95% CI [2.85-4.78]).<h4>Conclusion</h4>This meta-analysis provides reassuring evidence that adjunctive SGLT2 inhibitor use is not associated with increased fracture risk in insulin-treated patients with T1DM patients.